Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 267-274

  Weycker, Derek ^a   Malin, Jennifer ^b   Barron, Rich ^c   Edelsberg, John ^a   Kartashov, Alex ^a   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c AMGEN INC   (United States)

Author keywords

febrile neutropenia; filgrastim; outcomes; pegfilgrastim; sargramostim

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRESCRIPTION; PROSTATE CANCER; RECTUM CANCER; RISK ASSESSMENT; TRACHEA CANCER; TREATMENT DURATION;

EID: 85027924950     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31820dc075     Document Type: Article

References (29)

1. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuVant CMF in operable breast cancer: cohort study. BMJ. 2005;330:217
2. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuVant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21: 4524-4531
3. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24:3187-3205
4. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977
5. Amgen Inc, NEUPOGEN (Filgrastim) Package Insert, Thousand Oaks, CA; 2009
6. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170
7. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-1422
8. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med. 1990; 323:871-877
9. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A:319-324
10. Meibohm B, ed. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development: Integration of Pharmacokinetics and Pharmacodynamics Into the Drug Development of Pegfilgrastim, a Pegylated Protein Weinheim, Germany: WILEY-VCH Verlag GmbH and Co, KGaA; 2006:373-391
11. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-731
12. Amgen Inc, Neulasta (Pegfilgrastim) Package Insert, Thousand Oaks, CA; 2009
13. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29-25
14. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-909
15. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol. 2005;23:1178-1184
16. Bayer Inc, Leukine (Sargramostim) Package Insert, Pittsburg, PA; 2009
17. Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy- Induced neutropenia. Cancer. 2009;115:4839-4848
18. Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest. 1998; 16:366-373
19. Beveridge RA, Miller JA, Kales AN, et al. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGMCSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. 1997;5:289-298
20. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-348
21. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40:402-407
22. Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009;31:1069-1081
23. Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008;19:454-460
24. PublicWelfare-Protection of Human Subjects; 45CFR 46 y46.101
25. Health Insurance Portability and Accountability Act of 1996, 42 USC y1320-d2
26. National Comprehensive Cancer Network clinical practice guidelines in oncology. Myeloid growth factors. V1. 2009
27. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090
28. Ip EJ, Lee-Ma A, Troxell LS, et al. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Am J Health Syst Pharm. 2008;65: 1552-1555
29. Von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer Results from the GEPARTRIO study. Ann Oncol. 2008;19: 292-298